Quick verdict: DORM vs SON in 2026

In the head-to-head comparison of DORM vs SON stock comparison 2026, Sonoco Products Company (SON) holds the overall edge, leading in a majority of key metrics including growth, value, and overall profitability. SON demonstrates superior revenue growth, lower valuation multiples, and stronger net and EBITDA margins. While Dorman Products, Inc. (DORM) is the analyst favorite with higher buy ratings and a more ambitious consensus price target, SON shows significantly higher DCF upside. Not investment advice.

DORM vs SON: key metrics side by side

Full side-by-side comparison of DORM and SON across valuation, profitability, growth and analyst sentiment. Data updated 2026-04-23.

DORM vs SON valuation comparison

When assessing the DORM vs SON valuation, Sonoco Products Company (SON) appears significantly undervalued compared to Dorman Products, Inc. (DORM). SON boasts a P/E ratio of a mere 4.74x, which is substantially lower than DORM’s P/E of 16.48x. This suggests that investors are paying much less for each dollar of SON’s earnings. Similarly, SON’s Price-to-Book (P/B) ratio stands at 1.37x, while DORM trades at a higher P/B of 2.28x, indicating that SON’s assets are also priced more attractively relative to its market value.

Furthermore, the Discounted Cash Flow (DCF) analysis points to a massive potential upside for SON, estimated at +159.6% from its current price of $49.25, suggesting a fair value of $127.83. DORM, while also showing an upside, trails significantly with a DCF-implied upside of +32.8% from its current price of $109.41, indicating a fair value of $145.33. Based on these fundamental metrics, SON presents a compelling case for value investors looking for a stock that is currently cheaper on an earnings, asset, and intrinsic value basis. These figures highlight why SON stands out in the dorm vs son fundamentals and valuation analysis for investors seeking lower valuation multiples.

DORM vs SON growth comparison

In terms of growth, Sonoco Products Company (SON) clearly demonstrates stronger momentum when we compare DORM vs SON. SON reported an impressive year-over-year revenue growth of +41.7%, significantly outpacing Dorman Products, Inc. (DORM), which posted a revenue growth of +6.0%. This substantial difference in revenue expansion highlights SON’s more dynamic performance in scaling its business and capturing market share over the past year. This robust growth indicates a company in a strong expansion phase, which could be attractive to growth-oriented investors.

Beyond top-line growth, profitability margins also tell an interesting story about the companies’ operational efficiency. SON exhibits a higher EBITDA margin of 20.62% compared to DORM’s 16.89%, suggesting more efficient core operations. While DORM’s net margin of 9.59% is respectable, SON again leads with a net margin of 13.83%. These figures indicate that SON is not only growing revenue at a much faster pace but is also converting a larger portion of that revenue into profits before and after taxes. This combination of strong revenue growth and superior profitability margins suggests that SON has stronger overall momentum and operational leverage.

DORM vs SON profitability

Analyzing the DORM vs SON profitability, Sonoco Products Company (SON) exhibits stronger overall efficiency compared to Dorman Products, Inc. (DORM). SON’s net profit margin stands at 13.83%, which is notably higher than DORM’s 9.59%. This indicates that SON is more effective at converting its revenue into actual profit for shareholders, after all operating expenses, interest, and taxes have been accounted for. Furthermore, SON also shows a superior EBITDA margin of 20.62% against DORM’s 16.89%, underscoring its better operational efficiency before accounting for depreciation, amortization, interest, and taxes.

While both companies have an N/A% for Return on Equity (ROE) in the provided data, Free Cash Flow (FCF) yield offers another perspective on cash generation. SON’s FCF yield is a robust 5.47%, indicating a strong ability to generate cash relative to its market capitalization. DORM’s FCF yield is lower at 2.29%. A higher FCF yield is generally desirable as it signifies a company’s financial health and its capacity to fund operations, pay down debt, or return capital to shareholders. Therefore, in terms of generating more cash from its operations, SON clearly has the advantage.

Analyst ratings: DORM vs SON

When examining the analyst ratings for DORM vs SON, Dorman Products, Inc. (DORM) appears to be the more favored stock among institutional analysts. Of the 16 analysts covering DORM, an impressive 68.7% have issued a “Buy” rating. The consensus price target for DORM is $140, representing a significant potential upside of +28.0% from its current price of $109.41. This strong vote of confidence suggests that analysts believe DORM has substantial room for growth and could outperform its current market valuation.

In contrast, Sonoco Products Company (SON) has a lower percentage of “Buy” ratings, with 42.9% out of 21 analysts recommending a buy. While the consensus for SON is still a “Buy,” the analyst target price of $59.17 implies a more modest upside of +20.1% from its current price of $49.25. Despite SON’s strong fundamentals in other areas, analysts seem to have a more conservative outlook on its near-term price appreciation compared to DORM. This difference in analyst sentiment is a key factor to consider when evaluating should i buy dorm or son stock 2026.

Should I buy DORM or SON stock in 2026?

Deciding whether to buy DORM or SON stock in 2026 depends heavily on an investor’s specific objectives and risk tolerance. For growth investors, Sonoco Products Company (SON) presents a compelling case. Its remarkable year-over-year revenue growth of +41.7% significantly outpaces Dorman Products, Inc.’s (DORM) +6.0%. This strong top-line momentum, combined with superior net and EBITDA margins (SON: 13.83% net, 20.62% EBITDA vs DORM: 9.59% net, 16.89% EBITDA), suggests that SON is a more dynamic and efficient growth engine in the current market.

For value investors, SON also appears to be the more attractive option. Its P/E ratio of 4.74x and P/B ratio of 1.37x are substantially lower than DORM’s P/E of 16.48x and P/B of 2.28x, indicating a more favorable entry point based on earnings and assets. Furthermore, the DCF model projects an impressive +159.6% upside for SON, far exceeding DORM’s +32.8% DCF upside. These metrics underscore SON’s potential for significant intrinsic value realization, making it a stronger choice in the dorm vs son fundamentals and valuation comparison for those prioritizing value.

When considering income, neither DORM nor SON are standout dividend payers, as DORM currently offers a 0% dividend yield. However, SON does provide a very modest dividend yield of 0.04%. For investors primarily seeking dividend income, neither stock would be a primary choice, but SON offers at least a symbolic payout. Ultimately, while analysts show higher confidence in DORM’s price target, SON’s superior growth, valuation, and profitability metrics make it a potentially stronger pick for investors focused on both growth and value. This is not investment advice.

More DORM and SON comparisons

DORM full stock analysis · SON full stock analysis · All stock comparisons

FAQ: DORM vs SON